Phase 3 Alzheimer's Disease Trial, Not Yet Recruiting NCT07060391 Sponsor: Shanghai Jiao Tong University School of Medicine Condition: Alzheimer's Disease
Printed from Voxsanity (voxsanity.com.au) — NCT07060391 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Alzheimers Disease

Phase 3 Alzheimer's Disease Trial, Not Yet Recruiting

NCT07060391
Not Yet Recruiting Phase 3

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • The person has been clinically diagnosed with Alzheimer's disease and has a moderate to severe score on a cognitive function assessment.
  • The person is between 30 and 80 years old.
  • Both males and females are eligible.
  • The person or their family member has agreed to take part in the trial and has signed a consent form.
  • The person has no medical reasons that would prevent them from having surgery.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • The person has a history of radiation therapy or surgery involving the head or neck.
  • The person or their family is considered unlikely to follow the trial's rules and requirements consistently.
  • The person is not able to tolerate or safely undergo surgery.
  • The person has another condition, separate from Alzheimer's disease, that affects their thinking or memory.
  • The person is unable to tolerate treatment with the medication donepezil.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 August 2026

Contact this trial

Principal Investigator: Yijun Cheng, Doc, Ruijin Hospital

Phone: 15021058538

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 3
Sponsor
Shanghai Jiao Tong University School of Medicine
Registry
ClinicalTrials.gov
Start date
31 July 2025
Est. completion
31 January 2027

Primary endpoints

ADAS-cog score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Other trials for Alzheimer's Disease

  • NCT00869817 Washington University School of Medicine · Not Applicable · Recruiting · 🇦🇺 Australian site
  • NCT01793168 Sanford Health · Not Applicable · Recruiting · 🇦🇺 Australian site
  • NCT05194787 University of Tasmania · Not Applicable · Recruiting · 🇦🇺 Australian site
  • NCT05552157 Washington University School of Medicine · Phase 3 · Recruiting · 🇦🇺 Australian site
  • NCT06339190 Monash University · Not Applicable · Recruiting · 🇦🇺 Australian site

Browse all trials for Alzheimer's Disease →

Data last synced from ClinicalTrials.gov: 13 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov